Peptide Safety Checklist: 15 Rules Before You Start

Peptides are biologically active molecules. Unlike supplements, they interact directly with receptors, signaling pathways, and hormonal axes. That means the margin between "effective" and "problematic" is narrower than many users expect. This checklist covers the practical safety steps that reduce risk before and during any peptide protocol.

Before you start

1. Get baseline bloodwork

Before introducing any peptide that affects hormonal axes, get pre-protocol labs:

• GH secretagogues: IGF-1, fasting glucose, fasting insulin, HbA1c, comprehensive metabolic panel
• GLP-1 agonists: Fasting glucose, HbA1c, lipid panel, amylase, lipase, thyroid function
• BPC-157 / TB-500: No mandatory labs, but a baseline CBC and CMP are good practice
• Immune peptides (Tα1): CBC with differential, lymphocyte subsets if accessible

You cannot evaluate whether a peptide is "working" or causing harm without a baseline to compare against.

2. Verify your source

• Certificate of Analysis (CoA) from a third-party lab — not self-tested by the vendor
• HPLC purity > 98%
• Mass spectrometry confirmation of correct molecular weight
• Lot-specific testing (not generic "batch" certificates)

If a vendor cannot provide a current, lot-specific CoA with third-party verification, do not purchase.

3. Review contraindications

Absolute contraindications for most peptide classes:

• Active cancer or history of cancer (GH secretagogues elevate IGF-1, which is mitogenic)
• Pregnancy or breastfeeding (insufficient safety data for any research peptide)
• Active infection with fever (immune-modulating peptides can be unpredictable during acute illness)

Relative contraindications (discuss with a physician):

• Diabetes or pre-diabetes (GH secretagogues can impair glucose metabolism)
• History of pancreatitis (GLP-1 agonists carry a label warning)
• Autoimmune conditions (immune peptides can theoretically flare autoimmune processes)
• Concurrent prescription medications (drug interactions are poorly characterized)

4. Start one peptide at a time

If something goes wrong — side effect, lab value change, allergic reaction — you need to know which compound caused it. Starting multiple new peptides simultaneously makes attribution impossible. Add one peptide, stabilize for 2–4 weeks, then consider additions.

5. Read the reconstitution protocol

Peptides are sold lyophilized (freeze-dried). Reconstitution errors can destroy the peptide or introduce contamination:

• Use bacteriostatic water (BAC water), not sterile water — BAC water contains 0.9% benzyl alcohol, which prevents bacterial growth for up to 28 days
• Direct the water stream down the vial wall, not directly onto the lyophilized cake
• Swirl gently — never shake. Shaking causes foaming and can denature the peptide
• Calculate your concentration: mg of peptide ÷ mL of BAC water = mg/mL. Then convert to mcg per insulin syringe unit

During the protocol

6. Use proper injection technique

• Alcohol swab the injection site and the vial stopper before every use
• Subcutaneous injection: 45° angle, pinch the skin, inject slowly
• Rotate injection sites: Abdomen (1 inch from navel), outer thigh, upper arm. Same site repeatedly causes lipohypertrophy (hardened subcutaneous tissue that impairs absorption)
• Use insulin syringes (29–31 gauge) — thin enough to minimize tissue damage and pain

7. Store peptides correctly

• Lyophilized (unreconstituted): Refrigerator (2–8°C). Stable for months to years.
• Reconstituted: Refrigerator only. Use within 28 days. Never freeze reconstituted peptide.
• Never leave at room temperature for extended periods — peptides degrade faster at higher temperatures
• Protect from light — UV exposure can degrade certain peptides

8. Track your doses and timing

Log every injection: date, time, dose, injection site, and any immediate observations. This data is essential for:

• Identifying patterns if side effects emerge
• Ensuring consistent dosing (missed doses are the most common protocol error)
• Providing your physician with accurate information if needed

9. Monitor for side effects

Common side effects that are generally manageable:

• Injection site redness, swelling, or itching (technique or sensitivity issue)
• Flushing or warmth (common with CJC-1295 and some GHRPs)
• Mild nausea (common with GLP-1 agonists and PT-141, dose-dependent)
• Water retention (GH secretagogues — check hands, ankles)

Side effects that require immediate attention:

• Severe abdominal pain (GLP-1 agonists — rule out pancreatitis)
• Persistent headache or vision changes (intracranial pressure — rare)
• Signs of infection at injection site (expanding redness, warmth, pus)
• Allergic reaction (hives, swelling, difficulty breathing)

10. Get follow-up bloodwork

Repeat relevant labs at the midpoint (4–6 weeks) and end of your first cycle:

• Compare IGF-1, glucose, insulin to baseline
• Flag any direction of change that's concerning — even if values are still "in range"
• Trends matter more than individual values

Protocol discipline

11. Respect cycling protocols

GH secretagogues desensitize the GHSR (ghrelin receptor) with continuous use. Standard cycling: 12–16 weeks on, 4–8 weeks off. Hexarelin desensitizes faster — limit to 4–8 week cycles. Ignoring cycling doesn't produce better results; it produces worse results as receptor sensitivity declines.

12. Don't exceed recommended doses

More is not better. Most peptides have a dose-response curve that plateaus — higher doses produce more side effects without proportionally more benefit. Ipamorelin at 100–200 mcg produces 80–90% of the GH release achievable at 300 mcg, with significantly fewer side effects.

13. Don't combine without understanding interactions

Stacking redundant peptides (multiple ghrelin mimetics, GLP-1 + GLP-1) produces receptor saturation, not synergy. Stacking antagonistic peptides (GH secretagogues + exogenous HGH) produces pharmacological conflict. Understand the mechanism before combining.

14. Don't source from unverified channels

Peptides from unverified sources may contain:

• Wrong peptide entirely
• Sub-potent product (degraded or underdosed)
• Endotoxin contamination (bacterial byproducts from poor manufacturing)
• Heavy metal contamination

A low price is not a discount — it's a risk premium you pay with your health.

15. Have a discontinuation plan

Know in advance what would cause you to stop:

• Specific blood markers exceeding defined thresholds
• Side effects that persist beyond dose adjustment
• No measurable benefit after the full recommended duration
• Life circumstances that make consistent protocol adherence impossible

Peptides are tools with specific use cases. They are not indefinite lifestyle additions. Run the protocol, assess the results, and make an evidence-based decision about continuation.